Effect of mycophenolate mofetil on kallikrein expression in the kidney of 5/6 nephrectomized rats

Kidney and Blood Pressure Research

Volumn 25, Issue 5, 2002, Pages 289-295

  Ardiles, Leopoldo G ^a   Ehrenfeld, Pamela ^a   Quiroz, Yasmir ^b   Rodriguez Iturbe, Bernardo ^b   Herrera Acosta, Jaime ^c   Mezzano, Sergio ^a   Figueroa, Carlos D ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

5 6 nephrectomy; Hypertension; Immunohistochemistry; Mycophenolate mofetil; Renal ablation; Renal kallikrein

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; KALLIKREIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; HYPERTENSION; IMMUNOREACTIVITY; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY TUBULE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BLOOD PRESSURE; DRUG ANTAGONISM; IMMUNOHISTOCHEMISTRY; KIDNEY; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PRESSURE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KALLIKREINS; KIDNEY; KIDNEY TUBULES; MALE; MYCOPHENOLIC ACID; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0036435811     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066796     Document Type: Article

References (46)

1. Guder WG, Hallbach J: Localization and regulation of the renal kallikrein kinin system: Possible relations to renal transport functions. Klin Wochenschr 1988;66:849-856.
2. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80.
3. Vio CP, Loyola S, Velarde V: Localization of components of the kallikrein-kinin system in the kidney: Relation to renal function (State of the Art Lecture). Hypertension 1992;19 (suppl II):10-16.
4. Figueroa CD; Caorsi I, Subiabre J, Vio CP: Immunoreactive kallikrein localization in the rat kidney. J Histochem Cytochem 1984;32: 117-121.
5. Figueroa CD, MacIver AG, Mackenzie JC, Bhoola KD: Localisation of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 1988;89:437-442.
6. Guder WG, Hallbach J, Fink E, Kaissling B, Wirthensohn G: Kallikrein (kininogenase) in the mouse nephron: Effect of dietary potassium. Biol Chem 1987;368:637-645.
7. Clements JA: The glandular kallikrein family of enzymes: Tissue specific expression and hormonal regulation. Endocr Rev 1989;10:393-419.
8. Hermann A, Braun A, Figueroa CD, Müller-Esterl W, Fritz H, Rehbock J: Expression and cellular localization of kininogens in the human kidney. Kidney Int 1996;50:79-84.
9. Figueroa CD, Marchant A, Novoa U, Forster-mann U, Jarnagin K, Scholkens BA, Müller-Esterl W: Differential distribution of bradyki-nin B2 receptors in the rat and human cardiovascular system. Hypertension 2001;37:110-120.
10. 2 receptor in rat kidney by anti-peptide and anti-ligand antibodies. J Histochem Cytochem 1995;43:137-148.
11. Wilkinson R: Clinical approach to hypertension; in Cameron S, Davison A, Grünfeld JP, Kerr, D, Ritz E (eds): Textbook of Clinical Nephrology. London, Oxford University Press, 1992, vol 3, pp 2047-2058.
12. Peterson JC, Adler S, Burkart JM, Greene T, Herbert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease: The modification of diet in renal disease study. Ann Intern Med 1995;123:754-762.
13. Ishii M, Ikeda T, Takagi M, Sugimoto T, Atarashi K, Igari T, Uehara Y, Matsuoka H, Hirata Y, Kimura K Takeda T, Murao S: Elevated plasma catecholamines in hypertensives with primary glomerular diseases. Hypertension 1983;5:545-551.
14. Dzau V: Significance of the vascular renin angiotensin pathway. Hypertension 1986;8:553-559.
15. Cowley A, Roman R: The role of the kidney in hypertension. JAMA 1996;275:1581-1589.
16. Johnson RJ, Schreiner GF: Hypothesis: The role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension. Kidney Int 1997;52:1169-1179.
17. Hostetter TH, Olson JL, Venkatachalam MA, Brenner BM: Hyperfiltration of remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F93.
18. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
19. Kanazawa M, Abe K, Yasujima M, Yoshida K, Kohzuki M, Tanno M, Kasai Y, Omata K, Sato M, Takeuchi K: Role of renal kallikrein in the regulation of blood pressure in the rat remnant kidney model of chronic renal failure. Adv Exp Med Biol 1989;247B:121-125.
20. Shimamoto K, Ura N,Ishiguro T, Nakagawa M, Iimura O: The role of renal natriuretic depressor systems on hypertensive mechanisms in reduced renal mass hypertensive rats. Hypertens Res 1995;18:S53-S57.
21. MacLaughlin M, Montserrat AJ, Muller A, Matoso M, Amorena C: Role of kinins in the renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure. Kidney Blood Press Res 1998;21:329-334.
22. Nabokov A, Amann K, Gassmann P, Schwarz U, Orth SR: The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 1998;13:173-176.
23. Zoja C, Donadelli R, Corna D, Testa D, Facchinetti D, Maffi R, Luzzana E, Colosio V, Bertani T, Remuzzi G: The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis 1997;29:254-264.
24. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A: Combining an antipro-teinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999; 10:1542-1549.
25. Fujihara CK, Malheiros DM, Zatz R, Noronha ID: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998;54:1510-1519.
26. Luca ME, Paul LC, van Der Wal AM, Bruijn JA, de Heer E: Treatment with mycophenolate mofetil attenuates the development of Heymann nephritis. Exp Nephrol 2000;8:77-83.
27. Fujihara CK, Avancini DM, Noronha IL, De Nucci D, Zatz R: Mycophenolate mofetil reduces renal injury in the chronic nitric oxide synthase inhibition model. Hypertension 2001; 37:170-175.
28. Romero F, Rodriguez-Iturbe B, Parra G, Gon-zalez L, Herrera A, Tapia E: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999;55:945-955.
29. Zoja C, Perico N, Bergamelli A, Pasini M, Morigi M, Dadan J, Belloni A, Bertani T, Remuzzi G: Ticlopidine prevents renal disease progression in rats with reduced renal mass. Kidney Int 1990;37:934-942.
30. Valdes G, Figueroa CD, Corthorn J: Temporospatial changes of kallikrein-like enzymes during the estrous cycle and pregnancy in the rat uterus. Biol Reprod 1996;55:236-245.
31. Mezzano SA, Barría M, Droguett MA, Burgos ME, Ardiles LG, Flores C, Egido J: Tubular NF-κB and AP-1 activation in human proteinuric renal disease. Kidney Int 2001;60:1366-1377.
32. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubuloin-terstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1996;49:666-678.
33. Pardo-Mindan FJ, Errasti P, Panizo A, Sola I, de Alava E, Lozano MD: Decrease of apoptosis rate in patients with renal transplantation treated with mycophenolate mofetil. Nephron 1999;82:232-237.
34. Brater DC: Mycophenolate: Pharmacokinetics and dose adjustment; in, Rose BD (ed): UpTo-Date. Wellesley, MA, 2002.
35. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson R: Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 2001; 59:1626-1640.
36. Uehara Y, Hirawa N, Kawabata Y, Suzuki T, Ohshima N, Oka K, Ikeda T, Goto A, Toyo-oka T, Kizuki K: Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 1994;24:770-778.
37. Hirawa N, Uehara Y, Suzuki T, Kawabata Y, Numabe A, Gomi T, Ikeda T, Kizuki K, Omata M: Regression of glomerular injury by kalli-krein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event. Nephron 1999;81:183-193.
38. Wolf W, Yoshida H, Agata J, Chao L, Chao J: Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 2000;58:730-739.
39. Okuda S, Tsuruda H, Onoyama K, Oh Y, Mo-tomura K, Fujishima M: Effects of hypertension on the progress and prognosis of experimental focal glomerular sclerosis. Clin Sci 1986;71:23-29.
40. Klahr S., Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusec JW, Striker G: The effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease: Modification of diet in renal disease study group. N Engl J Med 1994;330:877-884.
41. Zucchelly P, Zuccala A: Progression of renal failure and hypertensive nephrosclerosis. Kidney Int 1998;54 (suppl):55-59.
42. Martinez-Maldonado M: Role of hypertension in the progression of chronic renal disease. Nephrol Dial Transplant 2001;16(suppl 1):63-66.
43. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
44. Gallagher AM, Yu H, Printz MP: Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension 1998;32: 84-88.
45. Kim NN, Villegas S, Summerour SR, Villarreal FJ: Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide. J Mol Cell Cardiol 1999;31:457-466.
46. Imamura A, Mackenzie HS, Lacy ER, Hutchison FN, Fitzbotton WR, Ploth DW: Effects of chronic teatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. Kidney Int 1995;47:1394-1402.